INHIBITORS OF BRUTON'S TYROSINE KINASE
10 Assignments
0 Petitions
Accused Products
Abstract
Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
252 Citations
100 Claims
-
1. (canceled)
-
2. (canceled)
-
3. (canceled)
-
4. (canceled)
-
5. (canceled)
-
6. (canceled)
-
7. (canceled)
-
8. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
12. (canceled)
-
13. (canceled)
-
14. (canceled)
-
15. (canceled)
-
16. (canceled)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
21. (canceled)
-
22. (canceled)
-
23. (canceled)
-
24. (canceled)
-
25. (canceled)
-
26. (canceled)
-
27. (canceled)
-
28. (canceled)
-
29. (canceled)
-
30. (canceled)
-
31. (canceled)
-
32. (canceled)
-
33. (canceled)
-
34. (canceled)
-
35. (canceled)
-
36. (canceled)
-
37. (canceled)
-
38. (canceled)
-
39. (canceled)
-
40. (canceled)
-
41. (canceled)
-
42. (canceled)
-
43. (canceled)
-
44. (canceled)
-
45. (canceled)
-
46. (canceled)
-
47. (canceled)
-
48. (canceled)
-
49. (canceled)
-
50. (canceled)
-
51. (canceled)
-
52. (canceled)
-
53. (canceled)
-
54. (canceled)
-
55. (canceled)
-
56. (canceled)
-
57. (canceled)
-
58. (canceled)
-
59. (canceled)
-
60. (canceled)
-
61. (canceled)
-
62. (canceled)
-
63. (canceled)
-
64. (canceled)
-
65. (canceled)
-
66. (canceled)
-
67. (canceled)
-
68. (canceled)
-
69. A method of identifying an irreversible inhibitor of a kinase selected from Btk, a Btk homolog, or a Btk kinase cysteine homolog comprising:
-
(1) contacting a multiplicity of kinases selected from Btk, a Btk homolog, or a Btk kinase cysteine homolog with a compound that comprises a Michael acceptor moiety; (2) contacting at least one non-kinase molecule having at least one accessible SH group with the compound that comprises a Michael acceptor moiety; and (3) determining the covalent binding of the compound that comprises a Michael acceptor with the multiplicity of kinases and the at least one non-kinase molecule; and repeating steps (1), (2), and (3) for at least one other compound that comprises a Michael acceptor moiety. - View Dependent Claims (70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)
-
-
84. (canceled)
-
85. (canceled)
-
86. (canceled)
-
87. (canceled)
-
88. (canceled)
-
89. (canceled)
-
90. (canceled)
-
91. (canceled)
-
92. (canceled)
-
93. (canceled)
-
94. (canceled)
-
95. (canceled)
-
96. (canceled)
-
97. (canceled)
-
98. (canceled)
-
99. (canceled)
-
100. (canceled)
Specification